Han Yao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Han Yao has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Donglai Wang
State Key Laboratory of Common Mechanism Research for Major Diseases & Department of Medical Genetics, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
6 shared publications - Wei Gu
Institute for Cancer Genetics, and Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians & Surgeons, Columbia University, New York, USA
5 shared publications - Xiaojun Yan
State Key Laboratory of Common Mechanism Research for Major Diseases & Department of Medical Genetics, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
5 shared publications - Yajing Liu
State Key Laboratory of Common Mechanism Research for Major Diseases & Department of Medical Genetics, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
5 shared publications - Zhen Wu
State Key Laboratory of Common Mechanism Research for Major Diseases & Department of Medical Genetics, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
5 shared publications - Dongkui Xu
Department of VIP , National Cancer Center & National Clinical Research Center for Cancer & Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , China
4 shared publications
Latest Publications
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-18 from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
Supplementary Figure 1 Host p53 regulates cancer immunotherapy in melanoma model. Supplementary Figure 2 Analysis of tumor-infiltrating cells in response to PI immunotherapy. Supplementary Figure 3 Cd8+ T cells are essential for tumor suppression in response to PI immunotherapy. Supplementary Figure 4 Establishment of PDX-based immunotherapeutic model with humanized mouse. Supplementary Figure 5 Further analysis of T cell-intrinsic p53 CTD acetylation in response to immunotherapy. Supplementary Figure 6 Generation of the p53fl7KR/fl7KR cKI mouse model. Supplementary Figure 7 CTD acetylation of T cell-intrinsic p53 contributes to PI immunotherapy in melanoma model. Supplementary Figure 8 Generation and characterization of p53fl7KQ/fl7KQ cKI mouse model. Supplementary Figure 9 Functional analysis of tumor-infiltrating T cells in p53+/-, Lck-Cre and p53fl7KQ/-, Lck-Cre mice. Supplementary Figure 10 CTD acetylation-mimicking p53 in T cells regulates antitumor immunity in melanoma model. Supplementary Figure 11 The effect of PI immunotherapy in p53fl7KQ/-, Lck-Cre recipient mice. Supplementary Figure 12 Activation of T cell-intrinsic p53 slightly enhances T cell-mediated cytotoxicity. Supplementary Figure 13 scRNA-seq analysis of tumor-infiltrating lymphocytes. Supplementary Figure 14 Functional analysis of Ccl5 in T cell-intrinsic p53-mediated antitumor immunity. Supplementary Figure 15 Activation of the IFN-γ pathway promotes Ccl5 transcriptional expression in Cd8+ T cells. Supplementary Figure 16 Further analysis of the crosstalk between p53 CTD acetylation and IFN-γ. Supplementary Figure 17 Mechanistic details of VPRBP-mediated repression of p53-dependent Ifng transcription. Supplementary Figure 18 Further analysis of IFN-γ/JAK-STAT pathways regulated by p53 CTD acetylation in Cd8+ T cells.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-18 from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
Supplementary Figure 1 Host p53 regulates cancer immunotherapy in melanoma model. Supplementary Figure 2 Analysis of tumor-infiltrating cells in response to PI immunotherapy. Supplementary Figure 3 Cd8+ T cells are essential for tumor suppression in response to PI immunotherapy. Supplementary Figure 4 Establishment of PDX-based immunotherapeutic model with humanized mouse. Supplementary Figure 5 Further analysis of T cell-intrinsic p53 CTD acetylation in response to immunotherapy. Supplementary Figure 6 Generation of the p53fl7KR/fl7KR cKI mouse model. Supplementary Figure 7 CTD acetylation of T cell-intrinsic p53 contributes to PI immunotherapy in melanoma model. Supplementary Figure 8 Generation and characterization of p53fl7KQ/fl7KQ cKI mouse model. Supplementary Figure 9 Functional analysis of tumor-infiltrating T cells in p53+/-, Lck-Cre and p53fl7KQ/-, Lck-Cre mice. Supplementary Figure 10 CTD acetylation-mimicking p53 in T cells regulates antitumor immunity in melanoma model. Supplementary Figure 11 The effect of PI immunotherapy in p53fl7KQ/-, Lck-Cre recipient mice. Supplementary Figure 12 Activation of T cell-intrinsic p53 slightly enhances T cell-mediated cytotoxicity. Supplementary Figure 13 scRNA-seq analysis of tumor-infiltrating lymphocytes. Supplementary Figure 14 Functional analysis of Ccl5 in T cell-intrinsic p53-mediated antitumor immunity. Supplementary Figure 15 Activation of the IFN-γ pathway promotes Ccl5 transcriptional expression in Cd8+ T cells. Supplementary Figure 16 Further analysis of the crosstalk between p53 CTD acetylation and IFN-γ. Supplementary Figure 17 Mechanistic details of VPRBP-mediated repression of p53-dependent Ifng transcription. Supplementary Figure 18 Further analysis of IFN-γ/JAK-STAT pathways regulated by p53 CTD acetylation in Cd8+ T cells.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
Although p53 plays a central role in tumor suppression, how it is regulated in T cells to exert antitumor effects remains unclear. In this study, we show that activation of T cell–intrinsic p53 via carboxyl-terminal domain (CTD) acetylation during immunotherapy activates the IFN-γ pathway, promotes CD8+ T-cell infiltration, and elicits CD8+ T cell–dependent antitumor immunity. Using T cell–specific knockin mouse models, we demonstrate that loss of CTD acetylation in T cells abrogates CD8+ T cell–dependent antitumor immunity whereas expression of CTD acetylation–mimicking p53 in T cells enhances this immune response. Moreover, we identify IFNG as a direct target of T cell–intrinsic p53 and uncover a positive feedback loop between p53 and the IFN-γ pathway for enhancing T cell–dependent antitumor immunity. Our study reveals that CTD acetylation–mediated activation of T cell–intrinsic p53 promotes antitumor immunity in response to immunotherapy, highlighting a non–tumor cell–autonomous mechanism of p53 action by regulating adoptive immune responses.Significance:This study identifies T cell–intrinsic p53 as a key determinant of immunotherapy efficacy. CTD acetylation, rather than stabilization, activates a p53–IFN-γ feedback loop and promotes CD8+ T cell–mediated antitumor immunity independently of tumor p53 status. These findings reveal a non–tumor cell–autonomous action of p53 to boost PD-1–based immunotherapy.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
Although p53 plays a central role in tumor suppression, how it is regulated in T cells to exert antitumor effects remains unclear. In this study, we show that activation of T cell–intrinsic p53 via carboxyl-terminal domain (CTD) acetylation during immunotherapy activates the IFN-γ pathway, promotes CD8+ T-cell infiltration, and elicits CD8+ T cell–dependent antitumor immunity. Using T cell–specific knockin mouse models, we demonstrate that loss of CTD acetylation in T cells abrogates CD8+ T cell–dependent antitumor immunity whereas expression of CTD acetylation–mimicking p53 in T cells enhances this immune response. Moreover, we identify IFNG as a direct target of T cell–intrinsic p53 and uncover a positive feedback loop between p53 and the IFN-γ pathway for enhancing T cell–dependent antitumor immunity. Our study reveals that CTD acetylation–mediated activation of T cell–intrinsic p53 promotes antitumor immunity in response to immunotherapy, highlighting a non–tumor cell–autonomous mechanism of p53 action by regulating adoptive immune responses.Significance:This study identifies T cell–intrinsic p53 as a key determinant of immunotherapy efficacy. CTD acetylation, rather than stabilization, activates a p53–IFN-γ feedback loop and promotes CD8+ T cell–mediated antitumor immunity independently of tumor p53 status. These findings reveal a non–tumor cell–autonomous action of p53 to boost PD-1–based immunotherapy.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Source Data 1 from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
This file contains the raw data of this study.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSource Data 1 from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
This file contains the raw data of this study.
- 19 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (1) , 155-176
Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
Although p53 plays a central role in tumor suppression, how it is regulated in T cells to exert antitumor effects remains unclear. In this study, we show that activation of T cell–intrinsic p53 via carboxyl-terminal domain (CTD) acetylation during immunotherapy activates the IFN-γ pathway, promotes CD8+ T-cell infiltration, and elicits CD8+ T cell–dependent antitumor immunity. Using T cell–specific knockin mouse models, we demonstrate that loss of CTD acetylation in T cells abrogates CD8+ T cell–dependent antitumor immunity whereas expression of CTD acetylation–mimicking p53 in T cells enhances this immune response. Moreover, we identify IFNG as a direct target of T cell–intrinsic p53 and uncover a positive feedback loop between p53 and the IFN-γ pathway for enhancing T cell–dependent antitumor immunity. Our study reveals that CTD acetylation–mediated activation of T cell–intrinsic p53 promotes antitumor immunity in response to immunotherapy, highlighting a non–tumor cell–autonomous mechanism of p53 action by regulating adoptive immune responses. Significance: This study identifies T cell–intrinsic p53 as a key determinant of immunotherapy efficacy. CTD acetylation, rather than stabilization, activates a p53–IFN-γ feedback loop and promotes CD8+ T cell–mediated antitumor immunity independently of tumor p53 status. These findings reveal a non–tumor cell–autonomous action of p53 to boost PD-1–based immunotherapy.
- 19 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (1) , 155-176
Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
Although p53 plays a central role in tumor suppression, how it is regulated in T cells to exert antitumor effects remains unclear. In this study, we show that activation of T cell–intrinsic p53 via carboxyl-terminal domain (CTD) acetylation during immunotherapy activates the IFN-γ pathway, promotes CD8+ T-cell infiltration, and elicits CD8+ T cell–dependent antitumor immunity. Using T cell–specific knockin mouse models, we demonstrate that loss of CTD acetylation in T cells abrogates CD8+ T cell–dependent antitumor immunity whereas expression of CTD acetylation–mimicking p53 in T cells enhances this immune response. Moreover, we identify IFNG as a direct target of T cell–intrinsic p53 and uncover a positive feedback loop between p53 and the IFN-γ pathway for enhancing T cell–dependent antitumor immunity. Our study reveals that CTD acetylation–mediated activation of T cell–intrinsic p53 promotes antitumor immunity in response to immunotherapy, highlighting a non–tumor cell–autonomous mechanism of p53 action by regulating adoptive immune responses. Significance: This study identifies T cell–intrinsic p53 as a key determinant of immunotherapy efficacy. CTD acetylation, rather than stabilization, activates a p53–IFN-γ feedback loop and promotes CD8+ T cell–mediated antitumor immunity independently of tumor p53 status. These findings reveal a non–tumor cell–autonomous action of p53 to boost PD-1–based immunotherapy.
- Open Access
- 1 July 2023
- Published by KEAI Publishing in Fundamental Research
- Vol. 3 (4) , 647-654
Alternatively mechanistic insights into acetylation in p53-mediated transcriptional regulation of cancer cell-intrinsic PD-1
Since the recent discovery of cancer cell-intrinsic programmed cell death protein-1 (PD-1), the mechanisms that manipulate PD-1 functions in tumor development beyond its immune checkpoint roles have become attractive research topics in oncology. Our previous study validated that PD-1 exists in lung cancer cells and is directly transactivated by p53 in a DNA-binding domain (DBD) acetylation-dependent manner. Here, we report that the carboxyl-terminal domain (CTD) of p53 likewise participates in PD-1 transcriptional regulation in cancer cells un-der different regulatory mechanisms. By mutating the lysine residues within the CTD to mimic either acetylation-deficient or fully acetylated status, we proved that acetylated CTD dramatically impeded p53-mediated trans-activation of PD-1. Furthermore, we identified bromodomain-containing protein 4 (BRD4) as a transcriptional coactivator of p53 that facilitates p53-mediated PD-1 transcription. Mechanistically, BRD4 specifically bound to the unacetylated CTD of p53, while CTD acetylation almost completely destroyed the BRD4-p53 interac-tion and thus led to compromised PD-1 expression. Collectively, this study unveils an alternative mechanism of p53 acetylation-directed PD-1 transcriptional regulation, which would broaden our current understanding of the molecular regulatory network of cancer cell-intrinsic PD-1.
- 1 July 2023
- Published by KEAI Publishing in Fundamental Research
- Vol. 3 (4) , 647-654
Open AccessAlternatively mechanistic insights into acetylation in p53-mediated transcriptional regulation of cancer cell-intrinsic PD-1
Since the recent discovery of cancer cell-intrinsic programmed cell death protein-1 (PD-1), the mechanisms that manipulate PD-1 functions in tumor development beyond its immune checkpoint roles have become attractive research topics in oncology. Our previous study validated that PD-1 exists in lung cancer cells and is directly transactivated by p53 in a DNA-binding domain (DBD) acetylation-dependent manner. Here, we report that the carboxyl-terminal domain (CTD) of p53 likewise participates in PD-1 transcriptional regulation in cancer cells un-der different regulatory mechanisms. By mutating the lysine residues within the CTD to mimic either acetylation-deficient or fully acetylated status, we proved that acetylated CTD dramatically impeded p53-mediated trans-activation of PD-1. Furthermore, we identified bromodomain-containing protein 4 (BRD4) as a transcriptional coactivator of p53 that facilitates p53-mediated PD-1 transcription. Mechanistically, BRD4 specifically bound to the unacetylated CTD of p53, while CTD acetylation almost completely destroyed the BRD4-p53 interac-tion and thus led to compromised PD-1 expression. Collectively, this study unveils an alternative mechanism of p53 acetylation-directed PD-1 transcriptional regulation, which would broaden our current understanding of the molecular regulatory network of cancer cell-intrinsic PD-1.
- Open Access
- 2 April 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (14) , eabf4148
An unexpected role for p53 in regulating cancer cell–intrinsic PD-1 by acetylation
Activation of PD-1 by p53 is critical for its tumor suppression in an immunity-independent manner.
- 2 April 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (14) , eabf4148
Open AccessAn unexpected role for p53 in regulating cancer cell–intrinsic PD-1 by acetylation
Activation of PD-1 by p53 is critical for its tumor suppression in an immunity-independent manner.